Fermenta Biotech Receives CEP from EDQM for VITADEE™ 100 SD, Boosting Global Growth
Fermenta Biotech Limited, a leading manufacturer of pharmaceutical and nutritional ingredients, has announced the receipt of the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its product VITADEE™ 100 SD - CHOLECALCIFEROL CONCENTRATE (POWDER FORM) 100, 000 IU/g. This makes Fermenta one of the only two companies globally to hold a CEP for this variant of Vitamin D3. The CEP underscores Fermenta's adherence to stringent European Pharmacopoeial Standards for manufacturing and product quality. This recognition enhances Fermenta's international footprint and its capability to deliver products that meet the highest global quality and regulatory standards, aligning with its mission to expand its global presence and create meaningful impact across the health and nutrition industry.
Key Highlights
- Fermenta Biotech has received a CEP from the EDQM for its product VITADEE™ 100 SD.
- This makes Fermenta one of the only two companies globally to hold a CEP for this variant of Vitamin D3.
- The CEP underscores Fermenta's adherence to stringent European Pharmacopoeial Standards.
- This recognition enhances Fermenta's international footprint and its capability to deliver high-quality products.
- This achievement aligns with Fermenta's mission to expand its global presence and create meaningful impact across the health and nutrition industry.